Dr. Accordino on Data From the PEARL Trial in HR+/HER2-  Metastatic Breast Cancer

Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast Cancer

Melissa K. Accordino, MD, MS, assistant professor of medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the findings of the phase III PEARL trial in hormone receptor–positive, HER2-negative metastatic breast cancer. Website: https://www.onclive.com Twitter:   / onclive   Facebook:   / onclive   LinkedIn:   / onclive